Tibet AIM Pharm. Inc.
002826.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.37B
Close$
$14.60
10.1% downside
Current Fair Value
10.1% downsideOvervalued by 10.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.37 Billion |
|---|---|
| Enterprise Value | $2.90 Billion |
| Dividend Yield | $0.15 (0.85%) |
| Earnings per Share | $0.5 |
| Beta | 0.37 |
| Outstanding Shares | 191,821,308 |
Return
| Return on Equity | 14.09% |
|---|---|
| Return on Assets | 10.17% |
| Return on Invested Capital | 16.89% |
Valuation & Multiples
| P/E Ratio | 26.81 |
|---|---|
| PEG | 17.79 |
| Price to Sales | 5.41 |
| Price to Book Ratio | 4.06 |
| Enterprise Value to Revenue | 4.24 |
| Enterprise Value to EBIT | 19.78 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Tibet AIM Pharm. Inc.
405 employees
CEO: Zhou Min Headquartered in Beijing, China, Tibet AIM Pharm. Inc. was established in 2003 to conduct research and develop medical products across China. The company's diverse pharmaceutical portfolio targets a range of health conditions. Among its ...